Myalgic Encephalomyelitis/Chronic Fatigue Syndrome as a Hyper-Regulated Immune System Driven by an Interplay Between Regulatory T Cells and Chronic Human Herpesvirus Infections

Autoimmunity and chronic viral infections are recurrent clinical observations in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a complex disease with an unknown cause. Given these observations, the regulatory CD4+ T cells (Tregs) show promise to be good candidates for the underlying pathology due to their capacity to suppress the immune responses against both self and microbial antigens. Here, we discussed the overlooked role of these cells in the chronicity of Human Herpes Virus 6 (HHV6), Herpes Simplex 1 (HSV1), and Epstein–Barr virus (EBV), as often reported as triggers of ME/CFS. Using simulations of the cross-regulation model for the dynamics of Tregs, we illustrated that mild infections might lead to a chronically activated immune responses under control of Tregs if the responding clone has a high autoimmune potential. Such infections promote persistent inflammation and possibly fatigue. We then hypothesized that ME/CFS is a condition characterized by a predominance of this type of infections under control of Tregs. In contrast, healthy individuals are hypothesized to trigger immune responses of a virus-specific clone with a low autoimmune potential. According to this hypothesis, simple model simulations of the CD4+ T-cell repertoire could reproduce the increased density and percentages of Tregs observed in patients suffering from the disease, when compared to healthy controls. A deeper analysis of Tregs in the pathogenesis of ME/CFS will help to assess the validity of this hypothesis.

[1]  Mónica A. Farías,et al.  Herpes Simplex Virus Type 1 Infection of the Central Nervous System: Insights Into Proposed Interrelationships With Neurodegenerative Disorders , 2019, Front. Cell. Neurosci..

[2]  E. Mignot,et al.  Autoimmunity to hypocretin and molecular mimicry to flu in type 1 narcolepsy , 2018, Proceedings of the National Academy of Sciences.

[3]  M. Mehta,et al.  Mitochondrial complex III is essential for regulatory T cell suppressive function , 2018, Nature.

[4]  T. Harrer,et al.  Chronic viral infections in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) , 2018, Journal of Translational Medicine.

[5]  M. Pawlita,et al.  Cytomegalovirus (CMV) seroprevalence in the adult population of Germany , 2018, PloS one.

[6]  D. Al-Sadeq,et al.  Epstein–Barr Virus Epidemiology, Serology, and Genetic Variability of LMP-1 Oncogene Among Healthy Population: An Update , 2018, Front. Oncol..

[7]  C. Scheibenbogen,et al.  Myalgic Encephalomyelitis/Chronic Fatigue Syndrome - Evidence for an autoimmune disease. , 2018, Autoimmunity reviews.

[8]  J. Rivas,et al.  Association of T and NK Cell Phenotype With the Diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) , 2018, Front. Immunol..

[9]  S. Hauser,et al.  B‐cell Therapy for Multiple Sclerosis: Entering an era , 2018, Annals of neurology.

[10]  J. W. Lindsey,et al.  Antibodies to the Epstein-Barr virus proteins BFRF3 and BRRF2 cross-react with human proteins , 2017, Journal of Neuroimmunology.

[11]  Mark M. Davis,et al.  Cytokine signature associated with disease severity in chronic fatigue syndrome patients , 2017, Proceedings of the National Academy of Sciences.

[12]  U. Reimer,et al.  Serological profiling of the EBV immune response in Chronic Fatigue Syndrome using a peptide microarray , 2017, PloS one.

[13]  D. Pierson,et al.  Latent virus reactivation in astronauts on the international space station , 2017, npj Microgravity.

[14]  L. Nacul,et al.  How have selection bias and disease misclassification undermined the validity of myalgic encephalomyelitis/chronic fatigue syndrome studies? , 2017, Journal of health psychology.

[15]  D. Levy-bruhl,et al.  Seroprevalence of cytomegalovirus infection in France in 2010 , 2017, Epidemiology and Infection.

[16]  A. Régnault,et al.  Narcolepsy Type 1 Is Associated with a Systemic Increase and Activation of Regulatory T Cells and with a Systemic Activation of Global T Cells , 2017, PloS one.

[17]  M. Moschos,et al.  Herpes simplex virus keratitis: an update of the pathogenesis and current treatment with oral and topical antiviral agents , 2016, Clinical & experimental ophthalmology.

[18]  Raluca Eftimie,et al.  Mathematical Models for Immunology: Current State of the Art and Future Research Directions , 2016, Bulletin of mathematical biology.

[19]  J. Ng,et al.  Regulatory T, natural killer T and γδ T cells in multiple sclerosis and chronic fatigue syndrome/myalgic encephalomyelitis: a comparison. , 2016, Asian Pacific journal of allergy and immunology.

[20]  L. Sechi,et al.  Humoral cross reactivity between α-synuclein and herpes simplex-1 epitope in Parkinson's disease, a triggering role in the disease? , 2016, Journal of Neuroimmunology.

[21]  A. Palotás,et al.  Genome-wide association analysis identifies genetic variations in subjects with myalgic encephalomyelitis/chronic fatigue syndrome , 2016, Translational Psychiatry.

[22]  D. Green,et al.  Autophagy enforces functional integrity of regulatory T cells by coupling environmental cues and metabolic homeostasis , 2015, Nature Immunology.

[23]  Underhill Ra Myalgic encephalomyelitis, chronic fatigue syndrome: An infectious disease , 2015 .

[24]  M. Buckland,et al.  Chronic fatigue syndrome and circulating cytokines: A systematic review , 2015, Brain, Behavior, and Immunity.

[25]  Ø. Fluge,et al.  B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment , 2015, PloS one.

[26]  D. Pierson,et al.  Multiple latent viruses reactivate in astronauts during Space Shuttle missions , 2014, Brain, Behavior, and Immunity.

[27]  Shalini Sharma,et al.  Herpes virus entry mediator (HVEM) modulates proliferation and activation of regulatory T cells following HSV-1 infection. , 2014, Microbes and infection.

[28]  M. Berk,et al.  The Emerging Role of Autoimmunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/cfs) , 2014, Molecular Neurobiology.

[29]  S. Schaffert,et al.  The interplay between Epstein–Barr virus and B lymphocytes: implications for infection, immunity, and disease , 2014, Immunologic Research.

[30]  N. Unterwalder,et al.  Deficient EBV-Specific B- and T-Cell Response in Patients with Chronic Fatigue Syndrome , 2014, PloS one.

[31]  F. Wang,et al.  Development of Virus-Specific CD4+ and CD8+ Regulatory T Cells Induced by Human Herpesvirus 6 Infection , 2013, Journal of Virology.

[32]  R. Ribeiro,et al.  Mechanisms Underlying CD4+ Treg Immune Regulation in the Adult: From Experiments to Models , 2013, Front. Immunol..

[33]  M. Maes,et al.  Myalgic encephalomyelitis/chronic fatigue syndrome and encephalomyelitis disseminata/multiple sclerosis show remarkable levels of similarity in phenomenology and neuroimmune characteristics , 2013, BMC Medicine.

[34]  E. Waubant,et al.  Rituximab in Relapsing and Progressive Forms of Multiple Sclerosis: A Systematic Review , 2013, PloS one.

[35]  Pablo Villoslada,et al.  Dynamic cross-regulation of antigen-specific effector and regulatory T cell subpopulations and microglia in brain autoimmunity , 2013, BMC Systems Biology.

[36]  A. Madrigal,et al.  Interaction between natural killer cells and regulatory T cells: perspectives for immunotherapy , 2013, Cellular and Molecular Immunology.

[37]  B. Clotet,et al.  Screening NK-, B- and T-cell phenotype and function in patients suffering from Chronic Fatigue Syndrome , 2013, Journal of Translational Medicine.

[38]  J. Lafaille,et al.  Induced CD4+Foxp3+ regulatory T cells in immune tolerance. , 2012, Annual review of immunology.

[39]  Michele A. Soltis,et al.  Frequency of Epitope-Specific Naive CD4+ T Cells Correlates with Immunodominance in the Human Memory Repertoire , 2012, The Journal of Immunology.

[40]  Ø. Fluge,et al.  Benefit from B-Lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome. A Double-Blind and Placebo-Controlled Study , 2011, PloS one.

[41]  Joaquín Goñi,et al.  Modeling the effector - regulatory T cell cross-regulation reveals the intrinsic character of relapses in Multiple Sclerosis , 2011, BMC Systems Biology.

[42]  N. Klimas,et al.  Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis , 2011, Journal of Translational Medicine.

[43]  F. Wang,et al.  Human Herpesvirus 6 Suppresses T Cell Proliferation through Induction of Cell Cycle Arrest in Infected Cells in the G2/M Phase , 2011, Journal of Virology.

[44]  N. Heveker,et al.  Herpes simplex virus type 1-induced FasL expression in human monocytic cells and its implications for cell death, viral replication, and immune evasion. , 2011, Viral immunology.

[45]  G. Ginsberg,et al.  Disruption of Intestinal CD4+ T Cell Homeostasis Is a Key Marker of Systemic CD4+ T Cell Activation in HIV-Infected Individuals , 2010, The Journal of Immunology.

[46]  A. Sant,et al.  Understanding the focused CD4 T cell response to antigen and pathogenic organisms , 2009, Immunologic research.

[47]  Irun R Cohen,et al.  Biomarkers, self-antigens and the immunological homunculus. , 2007, Journal of autoimmunity.

[48]  Jorge Carneiro,et al.  How Regulatory CD25+CD4+ T Cells Impinge on Tumor Immunobiology: The Differential Response of Tumors to Therapies , 2007, The Journal of Immunology.

[49]  N. Frenkel,et al.  Human Herpesvirus 6A (HHV-6A) and HHV-6B Alter E2F1/Rb Pathways and E2F1 Localization and Cause Cell Cycle Arrest in Infected T Cells , 2007, Journal of Virology.

[50]  Jorge Carneiro,et al.  How regulatory CD25(+)CD4(+) T cells impinge on tumor immunobiology? On the existence of two alternative dynamical classes of tumors. , 2007, Journal of theoretical biology.

[51]  A. Moosmann,et al.  Immunodominance of Lytic Cycle Antigens in Epstein-Barr Virus-Specific CD4+ T Cell Preparations for Therapy , 2007, PloS one.

[52]  C. van den Dool,et al.  When three is not a crowd: a Crossregulation Model of the dynamics and repertoire selection of regulatory CD4+ T cells , 2007, Immunological reviews.

[53]  M. Lederman,et al.  Microbial translocation is a cause of systemic immune activation in chronic HIV infection , 2006, Nature Medicine.

[54]  Daniel Rodríguez‐Pinto B cells as antigen presenting cells. , 2005, Cellular immunology.

[55]  L. Frappier,et al.  Functional characterization of EBV-encoded nuclear antigen 1-specific CD4+ helper and regulatory T cells elicited by in vitro peptide stimulation. , 2005, Cancer research.

[56]  T. Nomura,et al.  Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. , 2004, International immunology.

[57]  V. Levitsky,et al.  Capacity of Epstein-Barr virus to infect monocytes and inhibit their development into dendritic cells is affected by the cell type supporting virus replication. , 2004, The Journal of general virology.

[58]  H. D. de Melker,et al.  The seroepidemiology of herpes simplex virus type 1 and 2 in Europe , 2004, Sexually Transmitted Infections.

[59]  Jorge Carneiro,et al.  Tolerance and immunity in a mathematical model of T-cell mediated suppression. , 2003, Journal of theoretical biology.

[60]  Jeffrey A. Bluestone,et al.  Opinion-regulatory lymphocytes: Natural versus adaptive regulatory T cells , 2003, Nature Reviews Immunology.

[61]  V. Rivera,et al.  Cross‐reactivity with myelin basic protein and human herpesvirus‐6 in multiple sclerosis , 2003, Annals of neurology.

[62]  H. Mcdevitt,et al.  Tumor necrosis factor-α regulation of CD4+C25+ T cell levels in NOD mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[63]  A. Munnich,et al.  Trinucleotide repeat contraction: a pitfall in prenatal diagnosis of myotonic dystrophy , 2001, Journal of medical genetics.

[64]  J. Carneiro,et al.  Modelling T-cell-mediated suppression dependent on interactions in multicellular conjugates. , 2000, Journal of theoretical biology.

[65]  B. Gebhardt Evidence for antigenic cross-reactivity between herpesvirus and the acetylcholine receptor , 2000, Journal of Neuroimmunology.

[66]  P. Pellett,et al.  Human herpesvirus 6 , 1997, Clinical microbiology reviews.

[67]  Ian Hickie,et al.  The Chronic Fatigue Syndrome: A Comprehensive Approach to Its Definition and Study , 1994, Annals of Internal Medicine.

[68]  I. Cohen,et al.  Autoimmunity, microbial immunity and the immunological homunculus. , 1991, Immunology today.

[69]  T. Dyrberg,et al.  Molecular mimicry and myasthenia gravis. An autoantigenic site of the acetylcholine receptor alpha-subunit that has biologic activity and reacts immunochemically with herpes simplex virus. , 1989, The Journal of clinical investigation.

[70]  F. Matcham,et al.  Fatigue and psychosocial variables in autoimmune rheumatic disease and chronic fatigue syndrome: A cross-sectional comparison. , 2017, Journal of psychosomatic research.

[71]  Xiurong Zhao,et al.  Antibodies specific for Epstein-Barr virus nuclear antigen-1 cross-react with human heterogeneous nuclear ribonucleoprotein L. , 2016, Molecular immunology.

[72]  R. Underhill Myalgic encephalomyelitis, chronic fatigue syndrome: An infectious disease. , 2015, Medical hypotheses.

[73]  Tarek A-Z K Gaber,et al.  Multiple Sclerosis/Chronic Fatigue Syndrome overlap: When two common disorders collide. , 2014, NeuroRehabilitation.

[74]  J. Carneiro,et al.  Dynamics of Peripheral Regulatory and Effector T Cells Competing for Antigen Presenting Cells , 2011 .

[75]  Kara Hunter,et al.  Type 1 diabetes genes and pathways shared by humans and NOD mice. , 2005, Journal of autoimmunity.

[76]  P. Flor-Henry,et al.  Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome: Clinical Working Case Definition, Diagnostic and Treatment Protocols , 2003 .

[77]  Ray H. Baughman,et al.  Supporting Online Material , 2003 .